Duchenne Breakthrough Hopes Rise With More Data From Sarepta Gene Therapy
Phase II Data Bodes Well For Pivotal EMBARK Trial
Sarepta expect to complete dosing in their Phase III EMBARK study later this year, with a first readout then due in mid-2023 • Source: Shutterstock 
